AstraZeneca

Primary Screen Case Study

At Pelago Bioscience, we offer a high-throughput screening service based on CETSA® – a transformative, label-free assay for target engagement quantification in physiologically relevant contexts.

This case study illustrates how employing high-throughput screening with CETSA can deliver actionable data and result in significant time savings compared to other approaches.

Astra Zeneca Case Study - Pelago_1

Witness how AstraZeneca screened 500,000 compounds on a protein target, achieving superior hit rates and saving six months in the process.

Speak to our experts

Ready to streamline your screening processes and accelerate your drug discovery timeline?

Contact Us